Insulet Corp. Stock Plummets to New 52-Week Low of $182.27

Insulet Corp., a small-cap player in the Pharmaceuticals & Biotechnology industry, has reached a new 52-week low of USD 182.27 as of April 28, 2026. This decline marks a significant downturn for the stock, which has seen a 1-year performance of -4.78%, contrasting sharply with the S&P 500's impressive gain of 29.12% over the same period. The company's market capitalization stands at USD 15,815 million, with a price-to-earnings (P/E) ratio of 46.00, indicating a relatively high valuation compared to its earnings. Insulet Corp. has not offered dividends, maintaining a debt-to-equity ratio of 0.16, which suggests a conservative approach to leveraging. However, its return on equity is notable at 22.52%, reflecting a solid ability to generate profit from shareholders' equity. Despite healthy long-term growth in net sales at an annual rate of 24.53% and operating profit growth of 55.87%, the company has faced challenges, including a net profit decline of 24.56% over the past nine months. With high institutional holdings at 100%, Insulet Corp. remains under scrutiny as it navigates its current market position.